Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity. - Jamieson PJ; Shen X; Abu-Shmais AA; Wasdin PT; Janowska K; Edwards RJ; Scapellato G; Bukenya M; Bass LE; Richardson SI; Manamela NP; Liu S; et al. (Journal of virology, 2025)